Skip to main content

Table 1 Baseline characteristics at time of NRTI switching (week 0) between the two groups

From: Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens

Baseline characteristics EFV group
N = 28
NVP group
N = 34
P value
Gender: Female 8 (29%) 13 (38%) 0.590
Age, years, mean ± SD 35.5 ± 6.9 38.7 ± 8.3 0.110
Body weight, kilograms, mean ± SD 62.3 ± 9.8 62.7 ± 11.0 0.888
CD4 count, cells/mm3, mean ± SD 342 ± 147 381 ± 154 0.307
Serum creatinine, mg/dL, mean ± SD 0.78 ± 0.22 0.76 ± 0.16 0.758
eGFR, mL/min, median (IQR) 116 (98-134) 105 (188-123) 0.195
Serum phosphorus, mg/dL, mean ± SD 3.0 ± 0.5 3.0 ± 0.7 0.952
Serum uric acid, mg/dL, mean ± SD 5.1 ± 1.3 5.3 ± 1.6 0.575
Serum magnesium, mg/dL, mean ± SD 0.87 ± 0.23 0.92 ± 0.20 0.391
Serum alkaline phosphatase, mg/dL, mean ± SD 87 ± 23 89 ± 24 0.743